Metastatic disease in long bones: A proposed scoring system for diagnosing impending pathologic fractures. 1989.
Hilton Mirels
https://pubmed.ncbi.nlm.nih.gov/14600587Actively Recruiting
Age: 18Years +
All Genders
ID06524843
Generation of Synthetic Patient Data for Risk Evaluation of Bone Metastases Derived From Carcinoma
Led by Costantino Errani · Updated on 2025-12-15
250
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are reviewing medical records, radiological images, and histological data of approximately 750 patients treated for bone metastases from carcinoma at the Rizzoli Orthopaedic Institute between January 1, 2010, and December 31, 2022. This observational study aims to generate synthetic patient data to evaluate fracture risk related to bone metastases from various carcinomas. The study involves analyzing and reviewing existing clinical and imaging data from these patients without administering new treatments. It focuses on patients diagnosed with bone metastases regardless of carcinoma type, number, or location of metastases. The primary goal is to create a comprehensive dataset of clinical information and diagnostic images collected at baseline. Participants' involvement consists of data review and analysis based on available records and follow-up information from the last 12 months after diagnosis. Researchers will measure outcomes by compiling this dataset for risk evaluation. Since this is a retrospective observational study, no direct interventions or additional visits are required from participants. The study is expected to continue through December 2026.
CONDITIONS
Brief Title
Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of bone metastasis from carcinoma regardless of carcinoma type, number, or location of metastases
- Availability of imaging and clinical data
- At least one follow-up visit during the last 12 months from diagnosis
You will not qualify if you...
- Failure to meet any of the inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Diagnostic Evaluation
Duration - Baseline (Day 0)
Participants undergo review and analysis of imaging and clinical data related to bone metastases derived from carcinoma.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 12 months
Participants are observed with at least one follow-up visit within 12 months from diagnosis to monitor clinical status and outcomes.
At least 1 follow-up visit
Trial Site Locations
Total: 1 location
1
IRCCS Istituto Ortopedico Rizzoli
Bologna, Emilia-Romagna, Italy, 40134
Actively Recruiting
Loading map...
Research Team
C
Costantino Errani, MD
R
Roberta Laranga, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Clinical features of metastatic bone disease and risk of skeletal morbidity.
Robert E Coleman
https://pubmed.ncbi.nlm.nih.gov/17062708